Wallis CJD, et al. - An inquiry was set up with regard to the toxicity and effectiveness of contemporary metastatic castrate-resistant prostate cancer (mCRPC) treatments at a population-level, among all patients in Ontario particularly treated with newer agents including abiraterone, enzalutamide, docetaxel and cabazitaxel. No increased risk of hospitalizations and ER visits were illustrated for treatment-related complications for abiraterone or enzalutamide, among patients with mCRPC. On the other hand, treatment with intravenous chemotherapeutic agents was related to an increased risk of hospitalizations and ER visits to manage such complications.